LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer
Open Access
- 14 October 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy Nucleic Acids
- Vol. 22, 1004-1015
- https://doi.org/10.1016/j.omtn.2020.10.018
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
This publication has 45 references indexed in Scilit:
- Mutant p53: one name, many proteinsGenes & Development, 2012
- ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene PromotersOMICS: A Journal of Integrative Biology, 2011
- Curcumin ameliorates oxaliplatin‐induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivoInternational Journal of Cancer, 2010
- When mutants gain new powers: news from the mutant p53 fieldNature Reviews Cancer, 2009
- Suppression of Inhibitor of Differentiation 2, a Target of Mutant p53, Is Required for Gain-of-Function MutationsCancer Research, 2008
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- SW480, a p53 Double-mutant Cell Line Retains Proficiency for Some p53 FunctionsJournal of Molecular Biology, 2005
- Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II studyAnnals of Oncology, 2005
- Systemic Therapy for Colorectal CancerThe New England Journal of Medicine, 2005
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004